Income Statement (TTM)
Arecor Therapeutics plc Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
2020 12-31 |
2021 03-31 |
2021 06-30 |
2021 09-30 |
2021 12-31 |
2022 03-31 |
2022 06-30 |
2022 09-30 |
2022 12-31 |
2023 03-31 |
2023 06-30 |
2023 09-30 |
2023 12-31 |
2024 03-31 |
2024 06-30 |
2024 09-30 |
2024 12-31 |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 3 | 4 | 5 | 5 | 5 | 5 | 5 |
Change (%) | -10.51 | -11.75 | -6.82 | -7.32 | 10.06 | 9.14 | 36.38 | 26.67 | 20.31 | 16.88 | 17.67 | 15.02 | 3.56 | 3.44 | 1.57 | 1.55 | |
% of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
Cost Of Sales | 2 | 3 | 3 | 4 | |||||||||||||
Change (%) | 100.00 | 2.75 | |||||||||||||||
% of Revenue | 41.78 | 72.64 | 68.65 | 69.46 | |||||||||||||
Gross Operating Profit | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 3 | 4 | 5 | 5 | 5 | 2 | 2 |
Change (%) | -10.51 | -11.75 | -6.82 | -7.32 | 10.06 | 9.14 | 36.38 | 26.67 | 20.31 | 16.88 | 17.67 | 15.02 | 3.56 | 3.44 | -68.16 | -1.09 | |
% of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 31.35 | 30.54 |
SG&A | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 5 | 7 | 8 | 9 | 9 | 9 | 9 | 6 | 6 |
Change (%) | 19.87 | 16.58 | 2.06 | 2.01 | 1.13 | 1.12 | 60.13 | 37.55 | 25.91 | 20.58 | 4.55 | 4.36 | 2.28 | 2.23 | -31.59 | -3.10 | |
% of Revenue | 96.70 | 129.54 | 171.12 | 187.42 | 206.30 | 189.56 | 175.63 | 206.22 | 223.93 | 234.35 | 241.76 | 214.81 | 194.90 | 192.48 | 190.22 | 128.12 | 122.26 |
R&D | 4 | 4 | 4 | 5 | 5 | 7 | 8 | 8 | 9 | 8 | 7 | 6 | 6 | 6 | 5 | 4 | 3 |
Change (%) | 3.98 | 3.83 | 13.37 | 11.80 | 26.26 | 20.80 | 2.42 | 2.37 | -11.06 | -12.43 | -5.45 | -5.76 | -6.45 | -6.89 | -26.33 | -20.71 | |
% of Revenue | 231.80 | 269.35 | 316.89 | 385.58 | 465.11 | 533.58 | 590.58 | 443.54 | 358.43 | 264.98 | 198.52 | 159.52 | 130.70 | 118.06 | 106.27 | 77.08 | 60.18 |
OpEx | 5 | 6 | 6 | 7 | 7 | 8 | 10 | 11 | 13 | 13 | 13 | 14 | 14 | 14 | 14 | 13 | 12 |
Change (%) | 12.27 | 10.93 | 5.88 | 5.56 | 17.55 | 14.93 | 16.71 | 14.32 | 1.63 | 2.51 | 1.91 | 0.67 | 0.92 | 0.91 | -5.49 | -5.81 | |
% of Revenue | 301.88 | 378.74 | 476.05 | 540.97 | 616.15 | 658.10 | 693.03 | 593.09 | 535.25 | 452.16 | 396.57 | 343.47 | 300.63 | 292.95 | 285.77 | 265.90 | 246.63 |
Operating Income | -3 | -4 | -5 | -6 | -6 | -7 | -8 | -9 | -10 | -10 | -10 | -10 | -9 | -9 | -9 | -8 | -7 |
Change (%) | 23.55 | 19.06 | 9.26 | 8.48 | 19.01 | 15.97 | 13.40 | 11.81 | -2.66 | -1.57 | -4.22 | -4.41 | -0.40 | -0.40 | -9.30 | -10.25 | |
% of Revenue | -201.88 | -278.74 | -376.05 | -440.97 | -516.15 | -558.10 | -593.03 | -493.09 | -435.25 | -352.16 | -296.57 | -241.40 | -200.63 | -192.95 | -185.77 | -165.90 | -146.63 |
Interest Expense | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
Change (%) | 2.90 | 2.82 | -35.33 | -60.79 | -4.55 | -0.00 | -0.00 | 23.81 | -17.31 | 2.33 | -15.91 | -18.92 | 6.67 | 6.25 | 14.71 | 12.82 | |
% of Revenue | -4.83 | -5.55 | -6.47 | -4.49 | -1.90 | -1.65 | -1.51 | -1.11 | -1.08 | -0.74 | -0.65 | -0.47 | -0.33 | -0.34 | -0.35 | -0.39 | -0.44 |
Net Income | -3 | -4 | -5 | -5 | -6 | -7 | -7 | -8 | -9 | -9 | -9 | -9 | -9 | -9 | -9 | -9 | -10 |
Change (%) | 37.41 | 27.23 | 14.11 | 12.37 | 10.22 | 9.27 | 12.31 | 10.96 | 0.87 | 0.86 | -4.60 | -4.82 | 0.65 | 0.65 | 9.06 | 8.31 | |
% of Revenue | -162.07 | -248.87 | -358.79 | -439.39 | -532.73 | -533.50 | -534.15 | -439.91 | -385.35 | -323.09 | -278.81 | -226.04 | -187.05 | -181.80 | -176.89 | -189.93 | -202.57 |
Source: Capital IQ